Duvuru Geetha1,2, Zdenka Hruskova3, Marten Segelmark4, Jonathan Hogan5, Matthew D Morgan6, Teresa Cavero7, Per Eriksson8,9, Philip Seo10, Rebecca L Manno10, Jessica Dale11, Lorraine Harper6, Vladimir Tesar3, David Rw Jayne12. 1. Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. gduvura@jhmi.edu. 2. Johns Hopkins Bayview Medical Center, Johns Hopkins University, Baltimore, MD, 21224, USA. gduvura@jhmi.edu. 3. Department of Nephrology, Charles University, Prague, Czech Republic. 4. Department of Medicine, Linkoping University, Linkoping, Sweden. 5. Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, USA. 6. University of Birmingham, Birmingham, UK. 7. Hospital 12 de Octubre in Madrid, Madrid, Spain. 8. Department of Rheumatology, Linköping University, Linköping, Sweden. 9. Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 10. Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 11. School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. 12. Addenbrooke's Hospital, Cambridge, UK.
Abstract
BACKGROUND: Rituximab (RTX) is approved for remission induction in ANCA associated vasculitis (AAV). However, data on use of RTX in patients with severe renal disease is lacking. METHODS: We conducted a retrospective multi-center study to evaluate the efficacy and safety of RTX with glucocorticoids (GC) with and without use of concomitant cyclophosphamide (CYC) for remission induction in patients presenting with e GFR less than 20 ml/min/1.73 m(2). We evaluated outcomes of remission at 6 months (6 M), renal recovery after acute dialysis at diagnosis, e-GFR rise at 6 M, patient and renal survival and adverse events. RESULTS: A total 37 patients met the inclusion criteria. The median age was 61 years. (55-73), 62 % were males, 78 % had new diagnosis and 59 % were MPO ANCA positive. The median (IQR) e-GFR at diagnosis was 13 ml/min/1.73 m(2) (7-16) and 15 required acute dialysis. Eleven (30 %) had alveolar hemorrhage. Twelve (32 %) received RTX with GC, 25 (68 %) received RTX with GC and CYC and seventeen (46 %) received plasma exchange. The median (IQR) follow up was 973 (200-1656) days. Thirty two of 33 patients (97 %) achieved remission at 6 M and 10 of 15 patients (67 %) requiring dialysis recovered renal function. The median prednisone dose at 6 M was 6 mg/day. The mean (SD) increase in e-GFR at 6 months was 14.5 (22) ml/min/m(2). Twelve patients developed ESRD during follow up. There were 3 deaths in the first 6 months. When stratified by use of concomitant CYC, there were no differences in baseline e GFR, use of plasmapheresis, RTX dosing regimen or median follow up days between the groups. No differences in remission, renal recovery ESRD or death were observed. CONCLUSIONS: This study of AAV patients with severe renal disease demonstrates that the outcomes appear equivalent when treated with RTX and GC with or without concomitant CYC.
BACKGROUND:Rituximab (RTX) is approved for remission induction in ANCA associated vasculitis (AAV). However, data on use of RTX in patients with severe renal disease is lacking. METHODS: We conducted a retrospective multi-center study to evaluate the efficacy and safety of RTX with glucocorticoids (GC) with and without use of concomitant cyclophosphamide (CYC) for remission induction in patients presenting with e GFR less than 20 ml/min/1.73 m(2). We evaluated outcomes of remission at 6 months (6 M), renal recovery after acute dialysis at diagnosis, e-GFR rise at 6 M, patient and renal survival and adverse events. RESULTS: A total 37 patients met the inclusion criteria. The median age was 61 years. (55-73), 62 % were males, 78 % had new diagnosis and 59 % were MPO ANCA positive. The median (IQR) e-GFR at diagnosis was 13 ml/min/1.73 m(2) (7-16) and 15 required acute dialysis. Eleven (30 %) had alveolar hemorrhage. Twelve (32 %) received RTX with GC, 25 (68 %) received RTX with GC and CYC and seventeen (46 %) received plasma exchange. The median (IQR) follow up was 973 (200-1656) days. Thirty two of 33 patients (97 %) achieved remission at 6 M and 10 of 15 patients (67 %) requiring dialysis recovered renal function. The median prednisone dose at 6 M was 6 mg/day. The mean (SD) increase in e-GFR at 6 months was 14.5 (22) ml/min/m(2). Twelve patients developed ESRD during follow up. There were 3 deaths in the first 6 months. When stratified by use of concomitant CYC, there were no differences in baseline e GFR, use of plasmapheresis, RTX dosing regimen or median follow up days between the groups. No differences in remission, renal recovery ESRD or death were observed. CONCLUSIONS: This study of AAV patients with severe renal disease demonstrates that the outcomes appear equivalent when treated with RTX and GC with or without concomitant CYC.
Entities:
Keywords:
ANCA vasculitis; Renal disease; Rituximab
Authors: John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks Journal: N Engl J Med Date: 2010-07-15 Impact factor: 91.245
Authors: Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne Journal: N Engl J Med Date: 2010-07-15 Impact factor: 91.245
Authors: Robert A F de Lind van Wijngaarden; Herbert A Hauer; Ron Wolterbeek; David R W Jayne; Gill Gaskin; Niels Rasmussen; Laure-Hélène Noël; Franco Ferrario; Rüdiger Waldherr; E Christiaan Hagen; Jan A Bruijn; Ingeborg M Bajema Journal: J Am Soc Nephrol Date: 2006-07-06 Impact factor: 10.121
Authors: Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne Journal: Am J Kidney Dis Date: 2003-04 Impact factor: 8.860
Authors: David R W Jayne; Gill Gaskin; Niels Rasmussen; Daniel Abramowicz; Franco Ferrario; Loic Guillevin; Eduardo Mirapeix; Caroline O S Savage; Renato A Sinico; Coen A Stegeman; Kerstin W Westman; Fokko J van der Woude; Robert A F de Lind van Wijngaarden; Charles D Pusey Journal: J Am Soc Nephrol Date: 2007-06-20 Impact factor: 10.121
Authors: Michael A Paley; Fahad Edrees; Satoru Kudose; Joseph P Gaut; Prabha Ranganathan; Anitha Vijayan Journal: Saudi J Kidney Dis Transpl Date: 2019 Jan-Feb
Authors: Marta Casal Moura; Maria V Irazabal; Alfonso Eirin; Ladan Zand; Sanjeev Sethi; Bijan J Borah; Jeffrey L Winters; James P Moriarty; Rodrigo Cartin-Ceba; Alvise Berti; Misbah Baqir; Gwen E Thompson; Ashima Makol; Kenneth J Warrington; Viengneesee Thao; Ulrich Specks; Fernando C Fervenza Journal: J Am Soc Nephrol Date: 2020-08-21 Impact factor: 10.121
Authors: L Caroti; C L Cirami; L Di Maria; A Larti; P Carta; E Dervishi; S Farsetti; A Tsalouchos; L Novelli; E E Minetti Journal: BMC Nephrol Date: 2019-05-14 Impact factor: 2.388
Authors: Stephen P McAdoo; Nicholas Medjeral-Thomas; Seerapani Gopaluni; Anisha Tanna; Nicholas Mansfield; Jack Galliford; Megan Griffith; Jeremy Levy; Thomas D Cairns; David Jayne; Alan D Salama; Charles D Pusey Journal: Nephrol Dial Transplant Date: 2019-01-01 Impact factor: 5.992
Authors: Giorgio Trivioli; Seerapani Gopaluni; Maria L Urban; Davide Gianfreda; Matthias A Cassia; Paolo G Vercelloni; Marta Calatroni; Alessandra Bettiol; Pasquale Esposito; Corrado Murtas; Federico Alberici; Federica Maritati; Lucio Manenti; Alessandra Palmisano; Giacomo Emmi; Paola Romagnani; Gabriella Moroni; Gina Gregorini; Renato A Sinico; David R W Jayne; Augusto Vaglio Journal: Clin Kidney J Date: 2020-09-06
Authors: Hyeok Chan Kwon; Minyoung Kevin Kim; Jason Jungsik Song; Yong Beom Park; Sang Won Lee Journal: Yonsei Med J Date: 2020-08 Impact factor: 2.759